内科

目的对比分析奥卡西平与丙戊酸钠治疗对成人癫痫患者认知功能、生活质量及血清血管损伤因子水平的影响。方法选取2016年7月至2020年1月在我院住院治疗的成人癫痫患者103例，随机分为丙戊酸钠组（51例）和奥卡西平组（52例），分别给予丙戊酸钠及奥卡西平治疗，疗程6个月。比较两组患者治疗前后的认知功能（MMSE量表评分）、生活质量（QOLIE-31量表评分）、血清血管损伤因子水平以及不良反应发生情况。结果治疗前，两组患者的MMSE量表评分、QOLIE-31量表各维度评分比较差异无统计学意义（P＞0.05）；治疗6个月后，两组患者的MMSE量表评分、QOLIE-31量表各维度评分均显著增高，奥卡西平组患者的评分显著高于丙戊酸钠组，差异有统计学意义（P＜0.05）。治疗前，两组患者的血清血管损伤因子包括血清C反应蛋白(CRP)、同型半胱氨酸(Hcy)、二甲基精氨酸(ADMA)水平比较差异无统计学意义（P＞0.05）；治疗6个月后，两组患者的血清CRP、Hcy、ADMA水平均明显增高，但两组患者的血清CRP、Hcy、ADMA水平比较差异无统计学意义（P＞0.05）。治疗期间，两组患者的不良反应率比较差异无统计学意义（P＞0.05）。结论奥卡西平与丙戊酸钠治疗均会导致成人癫痫患者血清血管损伤因子水平增高，不良反应均较轻微，但奥卡西平治疗可更有效地提高患者的认知功能、改善患者生活质量。

ObjectiveTo compare and analyze the effects of oxcarbazepine and sodium valproate on cognitive function, life quality and serum vascular injury factors in adult patients with epilepsy. MethodA total of 103 adult patients with epilepsy who were treated and hospitalized in our hospital from July 2016 to January 2020 were enrolled. They were randomly divided into sodium valproate group (51 cases) and oxcarbazepine group (52 cases), sodium valproate and oxcarbazepine were respectively given to the two groups, for a six-month treatment course. The cognitive function (MMSE scale score), life quality (QOLIE-31 scale score), serum vascular injury factors levels and the occurrence of adverse reactions were compared between the two groups before and after treatment. ResultsBefore treatment, there were no statistically significant differences in the scores of the MMSE scale and QOLIE-31 scale between the two groups (P＞0.05). After 6 months of treatment, the scores of the MMSE scale and QOLIE-31 scale in each dimension significantly increased in both groups, and the abovementioned scores in the oxcarbazepine group were significantly higher than those in the sodium valproate group, with statistically significant differences (P＜0.05). Before treatment, there were no statistically significant differences in serum vascular injury factors, including serum C-reactive protein (CRP), homocysteine (Hcy) and dimethylarginine (ADMA) levels between the two groups (P＞0.05). After 6 months of treatment, the serum CRP, Hcy and ADMA levels of the two groups significantly increased, but there were no statistically significant differences in the serum CRP, Hcy, and ADMA levels between the two groups (P＞0.05). During the treatment, there was no statistically significant difference in the adverse reaction rate between the two groups (P＞0.05). ConclusionBoth oxcarbazepine and sodium valproate in treating adult patients with epilepsy can increase the level of serum vascular injury factors, with mild side effects; however, oxcarbazepine for treatment can more effectively improve the cognitive function, and improve the life quality in patients.